SEATTLE--(

西雅图--(

BUSINESS WIRE

商业热线

)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of Alan Colowick, M.D., M.P.H., of Matrix Capital Management Company to its Board of Directors.

)--AltPep Corporation是一家私营生物技术公司，开发淀粉样蛋白疾病的早期疾病缓解治疗和检测工具，今天宣布任命Matrix Capital Management company的医学博士Alan Colowick为其董事会成员。

“We are pleased to welcome Alan Colowick to the AltPep Board,” said Valerie Daggett, Ph.D., CEO and Founder of AltPep. “Alan’s deep experience as an investor, board member, and therapeutics industry leader will be invaluable as we position the company for our next phase of growth. His expertise will be particularly important as we advance our SOBIN therapeutics into Phase 1 clinical trials for Alzheimer’s and Parkinson’s diseases.”.

AltPep首席执行官兼创始人ValerieDaggett博士表示：“我们很高兴欢迎AlanColowick加入AltPep董事会。”。“艾伦作为投资者、董事会成员和治疗行业领导者的丰富经验将是非常宝贵的，因为我们将公司定位于下一个增长阶段。随着我们将SOBIN治疗技术推进阿尔茨海默氏病和帕金森氏病的一期临床试验，他的专业知识将尤为重要。”。

Alan Colowick remarked, “I am excited to join the AltPep Board at this pivotal point for the company. Its groundbreaking technology, aimed at targeting the early molecular triggers of amyloid diseases, truly sets AltPep apart from others in the field. I look forward to supporting AltPep’s efforts in advancing its unique and promising pipeline.

艾伦·科洛威克（Alan Colowick）表示：“在公司的这个关键时刻，我很高兴加入AltPep董事会。它的开创性技术旨在针对淀粉样蛋白疾病的早期分子触发因素，真正使AltPep在该领域与众不同。我期待着支持AltPep努力推进其独特而有前途的管道。

Positively affecting both disease treatment and detection has the potential to help countless patients suffering from amyloid diseases.”.

积极影响疾病治疗和检测有可能帮助无数患有淀粉样蛋白疾病的患者。”。

Alan Colowick, M.D., M.P.H. is Senior Managing Director on the Technology-Life Sciences team at Matrix Capital Management Company, LP and its affiliate, AyurMaya Capital Management Company, LP. He currently also serves on the BODs of Acelyrin Inc, Alumis Therapeutics, Solve Therapeutics, Personalis, Inc., AC Immune SA, Harpoon Therapeutics, Inc., InCarda Therapeutics, Inc., XyloCor Therapeutics, and Teon Therapeutics, Inc.

Alan Colowick，M.D.，M.P.H.是Matrix Capital Management Company，LP及其附属公司AyurMaya Capital Management Company，LP的技术生命科学团队的高级常务董事。他目前还在Acelyrin Inc，Alumis Therapeutics，Solve Therapeutics，Personalis，Inc.，AC Immune SA，Harpoon Therapeutics，Inc.，InCarda Therapeutics，Inc.，XyloCor Therapeutics和Teon Therapeutics，Inc.的董事会任职。

Prior to joining Matrix, Dr. Colowick was a Partner at Sofinnova Investments, where he was Chairman of the BOD of two portfolio companies and helped lead their successful acquisitions (Velos Bio acquired by Merck for $2.75B and Principia Biopharma, Inc. acquired by Sanofi for $3.7B). Prior to that, Dr.

在加入Matrix之前，Colowick博士是Sofinnova Investments的合伙人，在Sofinnova Investments担任两家投资组合公司的董事会主席，并帮助领导了他们的成功收购（默克以27.5亿美元收购了Velos Bio，赛诺菲以37亿美元收购了Principia Biopharma，Inc.）。在此之前，博士。

Colowick had an 18-year career in biotech including significant operating and executive roles at Amgen; Gloucester Pharmaceuticals, where he was CEO and led its acquisition by Celgene; and Celgene, where he was President of EMEA. Dr. Colowick received his M.D. from Stanford University and completed fellowship training in Hematology and Oncology at the Dana Farber Cancer Institute.

科洛威克在生物技术领域有18年的职业生涯，包括在安进担任重要的运营和执行职务；格洛斯特制药公司（Gloucester Pharmaceuticals），他担任首席执行官，并领导Celgene收购；还有塞尔金，他曾任欧洲、中东和非洲地区总裁。Colowick博士获得了斯坦福大学的医学博士学位，并在达纳法伯癌症研究所完成了血液学和肿瘤学的奖学金培训。

He also holds an M.P.H. from Harvard University..

他还拥有哈佛大学的硕士学位。。

About SOBA Diagnostics and SOBIN Therapeutics

关于SOBA Diagnostics和SOBIN Therapeutics

SOBIN therapeutics are in development for use in concert with early detection to target and neutralize the toxic soluble oligomers associated with amyloid diseases. SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases.

SOBIN疗法正在开发中，与早期检测结合使用，以靶向和中和与淀粉样蛋白疾病相关的有毒可溶性寡聚体。SOBA诊断是高度敏感的，正在开发的简单血液测试，以帮助诊断淀粉样疾病。

About AltPep Corporation

关于AltPep Corporation

AltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression.

AltPep正在开发针对淀粉样蛋白疾病的开创性疾病修饰治疗和检测工具，方法是针对早期分子触发因素：有毒可溶性寡聚体。我们定制的合成肽旨在选择性结合有毒寡聚体，以在整个疾病进展过程中检测和中和它们。

AltPep’s emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer’s and Parkinson’s diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep’s goal is to change the course of these debilitating diseases that affect over a billion people around the globe..

AltPep的重点是早期，症状前的检测和治疗。我们的主要项目集中在阿尔茨海默病和帕金森病，以及其他淀粉样蛋白疾病，如2型糖尿病，即将出现。AltPep的目标是改变这些影响全球10亿多人的衰弱疾病的进程。。

Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep’s innovative approach.

华盛顿大学Daggett研究小组数十年的科学研究为AltPep的创新方法奠定了基础。

For more information, please visit

有关更多信息，请访问

altpep.com

altpep.com

and follow us on

继续关注我们

LinkedIn

LinkedIn

.

.